A Study of Isoprinosine in Patients With Lymph Node Disease
Newport Pharmaceuticals International
Information provided by (Responsible Party)
NIH AIDS Clinical Trials Information Service
First received: November 2, 1999
Last updated: June 23, 2005
Last Verified: June 1989
History of Changes
The objectives of this study are to determine the effects of isoprinosine in patients
diagnosed as having unexplained generalized lymphadenopathy. Variables to be examined will
Signs and symptoms:
- Weight loss.
- Occurrence of opportunistic infections.
- T-helper cell (OKT4) numbers and proportions.
- T-suppressor cell (OKT8) numbers and proportions.
- Natural killer (NK) cell activity.
- Lymphocyte blastogenic response to phytohemagglutinin (PHA).
- Lymphocyte blastogenic response to pokeweed mitogen (PWM).
- Immunoglobulin (IgG, IgA, IgM, IgE, IgD) profile.
- Circulating immune complexes. Infections characteristically associated with AIDS, such as Candida albicans, Pneumocystis carinii pneumonia, Cytomegalovirus, Herpes simplex, Cryptococcus, Histoplasma, Toxoplasma, Cryptosporidium, Mycobacterium avium- intracellulare, Legionella, and Isospora.
- Blood chemistry including serum uric acid (PurposeA-12).
- Complete blood count (CBC).
Cell-mediated immune system parameters:
Drug : Inosine pranobex
Primary Purpose: Treatment
|Official Title:||A Multi-Center Double-Blind Placebo-Controlled Study to Investigate the Action of Isoprinosine (Inosiplex) in Patients With Unexplained Generalized Lymphadenopathy|
Further study details as provided by NIH AIDS Clinical Trials Information Service:
|Ages Eligible for Study:||18 Years and older|
|Sexes Eligible for Study:||Male|
|Accepts Healthy Volunteers:||No|
Patients with a history of gout, uric acid urolithiasis, uric acid nephrolithiasis, renal dysfunction, or gastric ulceration are excluded.
- Systemic corticosteroids.
- Cytotoxic immunosuppressive agents.
Critically ill patients or those with CDC-defined AIDS are excluded.
Excluded within 1 month of study entry:
Contacts and LocationsChoosing to participate in a study is an important personal decision.Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00002297
Locations Show More
|United States, California|
|Newport Pharmaceuticals International Inc|
|Laguna Hills, California, United States, 92656|
Sponsors and CollaboratorsNewport Pharmaceuticals International
|Responsible Party:||Newport Pharmaceuticals International|
|ClinicalTrials.gov Identifier:||NCT00002297 History of Changes|
|Other Study ID Numbers:||008A|
|Study First Received:||November 2, 1999|
|Last Updated:||June 23, 2005|
Keywords provided by NIH AIDS Clinical Trials Information Service:Inosine Pranobex
Additional relevant MeSH terms:
ClinicalTrials.gov processed this data on July 20, 2018
This information is provided by ClinicalTrials.gov.